
FDA approves adrabetadex (Lembaz) for Niemann-Pick disease type C with neurologic onset before age 6. Approval was based on a 55% lower risk of death vs matched external controls. Boxed warning: permanent hearing loss. hubs.li/Q04Fzz_s0 #Pediatrics #RareDisease













